| [1] |
Ganz PA, Land SR, Geyer CE Jr, et al. Menstrual history and quality-of-life outcomes in women with node-positive breast cancer treated with adjuvant therapy on the NSABP B-30 trial [J]．J Clin Oncol，2011, 29(9): 1110-1116.
|
| [2] |
廖宁. US Oncology 9735试验的最新随访结果[J]. 循证医学，2009, 9(2): 65.
|
| [3] |
谢联斌，谢莉，袁丽方．多西紫杉醇联合卡培他滨治疗蒽环类耐药晚期三阴性乳腺癌的临床观察[J/CD]．中华乳腺病杂志(电子版)，2010，4(3): 61-62.
|
| [4] |
李明卉，夏添松，王水．乳腺癌常用化疗药物的作用机制及血液学不良反应的研究进展[J/CD]. 中华乳腺病杂志(电子版)，2017，11(3): 186-190.
|
| [5] |
anonymous. CYP3A4 allele nomenclature [EB/OL]. [2017-02-08].
URL
|
| [6] |
anonymous. CYP3A5 allele nomenclature [EB/OL]. [2017-02-08].
URL
|
| [7] |
Baker SD, Verweij J, Cusatis GA, et al. Pharmacogenetic pathway analysis of docetaxel elimination[J]. Clin Pharmacol Ther, 2009, 85(2): 155-163.
|
| [8] |
Lepper ER, Baker SD, Permenter M, et al. Effect of common CYP3A4 and CYP3A5 variants on the pharmacokinetics of the cytochrome P450 3A phenotyping probe midazolam in cancer patients [J]. Clin Cancer Res, 2005, 11(20): 7398-7404.
|
| [9] |
Rodríguez-Antona C, Sayi JG, Gustafsson LL, et al. Phenotype-genotype variability in the human CYP3A locus as assessed by the probe drug quinine and analyses of variant CYP3A4 alleles[J]. Biochem Biophys Res Commu, 2005, 338(1): 299-305.
|
| [10] |
Tran A, Jullien V, Alexandre J, et al. Pharmacokinetics and toxicity of docetaxel: role of CYP3A, MDR1, and GST polymorphisms[J]. Clin Pharmacol Ther, 2006, 79(6): 570-580.
|
| [11] |
Tulsyan S, Chaturvedi P, Singh AK, et al. Assessment of clinical outcomes in breast cancer patients treated with taxanes: multi-analytical approach[J]. Gene, 2014, 543(1): 69-75.
|
| [12] |
周心娜，董宁宁，余靖，等．CYP3A5和GSTP1基因多态性与多西他赛联合塞替派治疗转移性乳腺癌近期疗效的相关性研究[J]．中国药学杂志，2012，47(2): 127-131.
|
| [13] |
Tsai SM, Lin CY, Wu SH, et al. Side effects after docetaxel treatment in Taiwanese breast cancer patients with CYP3A4, CYP3A5, and ABCB1 gene polymorphisms[J]. Clin Chim Acta, 2009，404(2): 160-165.
|
| [14] |
Kim KP, Ahn JH, Kim SB, et al. Prospective evaluation of the drug-metabolizing enzyme polymorphisms and toxicity profile of docetaxel in Korean patients with operable lymph node-positive breast cancer receiving adjuvant chemotherapy [J]. Cancer Chemother Pharmacol, 2012，69(5): 1221-1227.
|
| [15] |
赵苏，杨婉花. CYP3A4和CYP3A5基因多态性对多西他赛药动学和药效学影响的研究进展[J]. 世界临床药物，2015，36(9): 640-644.
|
| [16] |
Sim SC. CYP1B1 allele nomenclature [EB/OL]. [2017-02-08].
URL
|
| [17] |
任杰，李迺昶，李晓蕾，等．乳腺癌CYP1B1的表达对紫杉醇耐药性的影响[J]．中国肿瘤临床，2012，39(23): 1904-1908.
|
| [18] |
Sissung TM, Danesi R, Price DK, et al. Association of the CYP1B1*3 allele with survival in patients with prostate cancer receiving docetaxel[J]. Mol Cancer Ther, 2008, 7(1): 19-26.
|
| [19] |
Rizzo R, Spaggiari F, Indelli M, et al. Association of CYP1B1 with hypersensitivity induced by taxane therapy in breast cancer patients[J]. Breast Cancer Res Treat, 2010, 124(2): 593-598.
|
| [20] |
McFadyen MC, Cruickshank ME, Miller ID, et al. Cytochrome P450 CYP1B1 over-expression in primary and metastatic ovarian cancer[J]. Br J Cancer, 2001, 85(2): 242-246.
|
| [21] |
Fung KL, Pan J, Ohnuma S, et al. MDR1 synonymous polymorphisms alter transporter specificity and protein stability in a stable epithelial monolayer[J]. Cancer Res, 2014, 74(2): 598-608.
|
| [22] |
Haufroid V. Genetic polymorphisms of ATP-binding cassette transporters ABCB1 and ABCC2 and their impact on drug dispositio [J]. Curr Drug Targets, 2011, 12(5): 631-646.
|
| [23] |
Nakajima M, Fujiki Y, Kyo S, et al. Pharmacokinetics of paclitaxel in ovarian cancer patients and genetic polymorphisms of CYP2C8, CYP3A4, and MDR1 [J]. J Clin Pharmacol, 2005, 45(6): 674-682.
|
| [24] |
Fajac A, Gligorov J, Rezai K, et al. Effect of ABCB1 C3435T polymorphism on docetaxel pharmacokinetics according to menopausal status in breast cancer patients[J]. Br J Cancer, 2010, 103(4): 560-566.
|
| [25] |
黄萃园，张洪，彭锐，等. ABCB1(1199G>A)基因多态性对多西他赛转运影响的分子机制[J]．中国医院药学杂志，2016，36(21): 1864-1869.
|
| [26] |
Zhou Z, Chen Q, Zuo D, et al. ABCB1 (rs1128503) polymorphism and response to chemotherapy in patients with malignant tumors-evidences from a meta-analysis[J]. Int J Clin Exp Med, 2015, 8(1): 265-272.
|
| [27] |
Pan JH, Han JX, Wu JM, et al. MDR1 single nucleotide polymorphism G2677T/A and haplotype are correlated with response to docetaxel-cisplatin chemotherapy in patients with non-small-cell lung cancer[J]. Respiration, 2009, 78(1): 49-55.
|
| [28] |
Chang H, Rha SY, Jeung HC, et al. Association of the ABCB1 3435C>T polymorphism and treatment outcomes in advanced gastric cancer patients treated with paclitaxel-based chemotherapy[J]. Oncol Rep, 2010, 23(1): 271-278.
|
| [29] |
刘新兰，张海霞，赵岳阳，等．ABCB 1基因多态性对乳腺癌紫杉类药物化疗疗效的影响[J]．西安交通大学学报(医学版)，2016，37(3): 383-387.
|
| [30] |
Sissung TM, Baum CE, Deeken J, et al. ABCB1 genetic variation influences the toxicity and clinical outcome of patients with androgen-independent prostate cancer treated with docetaxel[J]. Clin Cancer Res, 2008, 14(14): 4543-4549.
|
| [31] |
杨晓琳．不同ABCB1基因型乳腺癌患者应用紫杉醇的安全性研究[J]．基层医学坛，2017，21(1): 25-26.
|
| [32] |
Zeng FF, Liu SY, Wei W, et al. Genetic polymorphisms of glutathione S-transferase T1 and bladder cancer risk: a meta-analysis[J]. Clin Exp Med, 2010, 10(1): 59-68.
|
| [33] |
Peklak-Scott C, Smitherman PK, Townsend AJ, et al. Role of glutathione S-transferase P1-1 in the cellular detoxification of cisplatin[J]. Mol Cancer Ther, 2008, 7(10): 3247-3255.
|
| [34] |
Deenen MJ, Cats A, Beijnen JH, et al. Part 3: Pharmacogenetic variability in phase Ⅱ anticancer drug metabolism [J]. Oncologist, 2011, 16(7): 992-1005.
|
| [35] |
Sweeney C, McClure GY, Fares MY, et al. Association between survival after treatment for breast cancer and glutathione S-transferase P1 Ile105Val polymorphism[J]. Cancer Res, 2000, 60(20): 5621-5624.
|
| [36] |
Kumaraswami K, Katkam SK, Aggarwal A, et al. Epistatic interactions among CYP2C19 *2, CYP3A4 and GSTP1 on the cyclophosphamide therapy in lupus nephritis patients[J]. Pharmacogenomics, 2017, 18(2): 1401-1411.
|
| [37] |
Ludovini V, Antognelli C, Rulli A, et al. Influence of chemotherapeutic drug-related gene polymorphisms on toxicity and survival of early breast cancer patients receiving adjuvant chemotherapy[J]. BMC Cancer, 2017, 17(1): 502.
|
| [38] |
江泽飞，许凤锐. 2016年乳腺癌精准医学发展：困境与出路[J/CD]. 中华乳腺病杂志(电子版)，2017，11(2): 65-68.
|